JP2024511996A5 - - Google Patents
Info
- Publication number
- JP2024511996A5 JP2024511996A5 JP2023557285A JP2023557285A JP2024511996A5 JP 2024511996 A5 JP2024511996 A5 JP 2024511996A5 JP 2023557285 A JP2023557285 A JP 2023557285A JP 2023557285 A JP2023557285 A JP 2023557285A JP 2024511996 A5 JP2024511996 A5 JP 2024511996A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- alkyl
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162460P | 2021-03-17 | 2021-03-17 | |
| US63/162,460 | 2021-03-17 | ||
| PCT/US2022/020700 WO2022197892A1 (en) | 2021-03-17 | 2022-03-17 | Purine derivatives as anticancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511996A JP2024511996A (ja) | 2024-03-18 |
| JP2024511996A5 true JP2024511996A5 (https=) | 2025-03-26 |
Family
ID=81327909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557285A Pending JP2024511996A (ja) | 2021-03-17 | 2022-03-17 | 抗がん剤としてのプリン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240059689A1 (https=) |
| EP (1) | EP4308566A1 (https=) |
| JP (1) | JP2024511996A (https=) |
| KR (1) | KR20240006509A (https=) |
| CN (1) | CN117425656A (https=) |
| AU (1) | AU2022238886A1 (https=) |
| BR (1) | BR112023018799A2 (https=) |
| CA (1) | CA3212292A1 (https=) |
| IL (1) | IL305991A (https=) |
| MX (1) | MX2023010909A (https=) |
| WO (1) | WO2022197892A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312642A (en) | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430049A4 (en) * | 2021-11-12 | 2025-12-17 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| CN117024253A (zh) * | 2023-08-14 | 2023-11-10 | 江西阿尔法高科药业有限公司 | 一种药用级麝香草酚特定杂质的制备方法 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025256544A1 (zh) * | 2024-06-11 | 2025-12-18 | 福建盛迪医药有限公司 | 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法 |
| CN119751316A (zh) * | 2024-12-20 | 2025-04-04 | 江南大学 | 一种1-苯基三氟甲基n-（氟磺酰基）氨基甲酸酯化合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| JP2011236198A (ja) * | 2010-04-13 | 2011-11-24 | Daiichi Sankyo Co Ltd | モルホリノプリン誘導体 |
| CN108473495B (zh) * | 2015-11-20 | 2022-04-12 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| US11485736B2 (en) * | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
-
2022
- 2022-03-17 WO PCT/US2022/020700 patent/WO2022197892A1/en not_active Ceased
- 2022-03-17 IL IL305991A patent/IL305991A/en unknown
- 2022-03-17 JP JP2023557285A patent/JP2024511996A/ja active Pending
- 2022-03-17 CN CN202280035481.2A patent/CN117425656A/zh active Pending
- 2022-03-17 BR BR112023018799A patent/BR112023018799A2/pt unknown
- 2022-03-17 AU AU2022238886A patent/AU2022238886A1/en not_active Abandoned
- 2022-03-17 CA CA3212292A patent/CA3212292A1/en active Pending
- 2022-03-17 MX MX2023010909A patent/MX2023010909A/es unknown
- 2022-03-17 EP EP22717473.7A patent/EP4308566A1/en active Pending
- 2022-03-17 KR KR1020237035424A patent/KR20240006509A/ko active Pending
-
2023
- 2023-09-15 US US18/468,385 patent/US20240059689A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024511996A5 (https=) | ||
| JP2021534168A5 (https=) | ||
| JP2021519783A5 (https=) | ||
| JP2022137047A5 (https=) | ||
| RU2472797C2 (ru) | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА | |
| JP2015529235A5 (https=) | ||
| HRP20201821T1 (hr) | Inhibitori arginaze i njihove terapeutske primjene | |
| CN110582483A (zh) | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 | |
| JP2023515235A5 (https=) | ||
| CA2674600A1 (en) | Formulations for cancer treatment | |
| JP2020517616A5 (https=) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2010516626A5 (https=) | ||
| JP2014514317A5 (https=) | ||
| CA3019450A1 (en) | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application | |
| JP2017128612A (ja) | Ａｒｒｙ−３８０の多形体、選択的ｅｒｂｂ２（ｈｅｒ２）阻害剤、およびそれらを含有する薬学的組成物 | |
| JP2011511095A5 (https=) | ||
| JP2015534975A5 (https=) | ||
| JP2015536986A5 (https=) | ||
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes | |
| RU2011113402A (ru) | ПИРИДО[5,4d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОЛИФЕРАЦИИ КЛЕТОК | |
| JP2020504716A5 (https=) | ||
| JP2016508969A5 (https=) | ||
| SG11202113307TA (en) | Cot modulators and methods of use thereof | |
| JP2023506787A5 (https=) |